Peptides vs steroids: separating hype from clinical evidence

What did @garrettwayne0 actually say?

The creator compared tesamorelin (spelled "TESIMRELIN" in the video) to HGH, arguing that peptides are superior because they stimulate your body's own growth hormone rather than replacing it externally. The core claim: injecting HGH "ends up most of the time shutting everything down" and relies on an exogenous source, while tesamorelin "tells your brain to release more of your own growth hormone" by pulsing natural receptors. The framing positions peptides as a smarter, more physiologically respectful alternative to traditional hormone therapy.

The creator also incorrectly categorized HGH as a steroid. That's worth flagging immediately. Human growth hormone is a peptide hormone, not an anabolic-androgenic steroid. These are different drug classes with different mechanisms, legal statuses, and risk profiles. Starting the comparison with a classification error sets a shaky foundation.

Does the science back this up?

Partially, yes. The mechanistic description of tesamorelin as a growth hormone-releasing hormone (GHRH) analogue is accurate. But the claim that HGH "shuts everything down most of the time" overstates the suppression risk significantly.

Tesamorelin is an FDA-approved GHRH analogue, specifically indicated for HIV-associated lipodystrophy (Egrifta, approved 2010). It works by binding to GHRH receptors in the pituitary, prompting pulsatile GH release. This pulsatile pattern does more closely mimic natural physiology compared to direct GH injection. Research by Stanley et al. (2012, Journal of Clinical Endocrinology and Metabolism) confirmed tesamorelin raises IGF-1 while preserving some pulsatile GH dynamics.

However, HGH suppression of endogenous production is dose-dependent and reversible in most cases. The "shuts everything down" framing implies permanent or total suppression, which is not supported by the clinical literature. Vance (1990, New England Journal of Medicine) noted that exogenous GH administration does suppress somatotroph function, but recovery typically occurs after discontinuation. The creator treats a conditional, dose-related effect as an absolute outcome.

What did they get wrong (or right)?

Right: The core mechanistic distinction between GHRH analogues and direct GH administration is real and worth understanding. Tesamorelin does stimulate endogenous release rather than replacing it, and that distinction has legitimate clinical relevance.

Wrong: HGH is not a steroid. This is a basic pharmacology error. Anabolic-androgenic steroids are synthetic derivatives of testosterone. Growth hormone is a 191-amino-acid peptide produced by the pituitary gland. Calling HGH a steroid in a video about "peptides vs steroids" misleads viewers about fundamental drug categories.

Also wrong: "Shuts everything down all the processes in your body" is not an accurate description of what exogenous HGH does. Liu et al. (2007, Annals of Internal Medicine) found that while exogenous GH use carries real risks including edema, glucose intolerance, and carpal tunnel syndrome, global systemic shutdown is not the clinical picture. Overstatement like this makes the peptide look better by making the comparison look worse than it is.

What should you actually know?

Tesamorelin is a legitimate pharmaceutical with actual FDA approval, real clinical trials, and a defined indication. That makes it unusual among the peptides circulating in wellness and bodybuilding communities. Most peptides discussed on social media, including BPC-157 and TB-500, have no approved clinical indication and are regulated as research chemicals in the United States.

The "stimulates your own production" framing is appealing, but it does not automatically mean safer or risk-free. Tesamorelin still elevates IGF-1, which carries its own considerations for people with certain health histories. Raun et al. (1998, European Journal of Endocrinology) documented that GHRH analogues meaningfully raise systemic IGF-1, a growth factor with complex effects across multiple tissue types.

If you are considering tesamorelin or any GHRH analogue outside of an FDA-approved clinical context, that conversation belongs with a licensed physician, not a TikTok comment section. Compounded versions of tesamorelin are not equivalent to the FDA-approved formulation, and their purity and dosing consistency have not been validated through the same regulatory process.